Abbott Laboratories
ABT
$135.08
-$2.63-1.91%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 7.16% | 4.85% | 4.00% | 2.23% | 1.49% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 7.16% | 4.85% | 4.00% | 2.23% | 1.49% |
| Cost of Revenue | 10.44% | 2.02% | 0.91% | 2.79% | -0.75% |
| Gross Profit | 4.58% | 7.20% | 6.52% | 1.77% | 3.31% |
| SG&A Expenses | 8.16% | 6.11% | 6.83% | 6.81% | -7.24% |
| Depreciation & Amortization | -3.33% | -5.24% | -5.42% | -3.87% | -3.02% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 10.35% | 3.19% | 1.79% | 3.83% | -2.96% |
| Operating Income | -4.90% | 12.72% | 14.91% | -5.77% | 22.71% |
| Income Before Tax | 13.09% | 16.10% | -1.77% | -8.07% | 35.98% |
| Income Tax Expenses | -3,681.59% | 25.11% | 16.86% | -13.52% | -29.97% |
| Earnings from Continuing Operations | 478.98% | 14.62% | -5.31% | -7.06% | 54.31% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 478.98% | 14.62% | -5.31% | -7.06% | 54.31% |
| EBIT | -4.90% | 12.72% | 14.91% | -5.77% | 22.71% |
| EBITDA | -3.75% | 7.79% | 10.29% | -3.90% | 15.77% |
| EPS Basic | 479.67% | 14.56% | -5.40% | -6.98% | 54.85% |
| Normalized Basic EPS | -6.92% | 16.05% | 11.86% | -5.30% | 19.48% |
| EPS Diluted | 479.43% | 14.63% | -5.40% | -6.67% | 55.01% |
| Normalized Diluted EPS | -6.92% | 16.14% | 11.86% | -5.26% | 19.48% |
| Average Basic Shares Outstanding | -0.11% | 0.04% | 0.06% | -0.09% | -0.34% |
| Average Diluted Shares Outstanding | -0.11% | -0.04% | 0.06% | -0.12% | -0.34% |
| Dividend Per Share | 7.27% | 7.84% | 7.84% | 7.84% | 7.84% |
| Payout Ratio | -0.81% | -0.06% | 0.14% | 0.16% | -0.30% |
